The Generation and Down-Regulation of the Immune Response to Progressive Tumors

  • Robert J. North
  • Antonio DiGiacomo
  • Earl S. Dye

Abstract

Determining whether a given animal or human tumor possesses antigens capable of evoking a specific antitumor immune response is essential before a rational attempt can be made to treat the tumor by a therapeutic modality designed to augment specific antitumor immunity. The role of the experimental tumor immunologists is to obtain detailed information about the immunogenicity of animal tumors and about the antitumor immune response they evoke, with a view to supplying the clinical oncologist with knowledge about the type of immune response that needs to be boosted. Regardless of whether or not animal tumors are suitable models of the human disease, the fact is that animal and human tumors have a lot in common, including the capacity to grow progressively in their hosts. Therefore, even though an animal tumor may possess tumor-specific antigens, it is not destroyed by specific or nonspecific host defense mechanisms.

Keywords

Depression Lymphoma Leukemia Influenza Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Foley, E. J., 1953, Antigenic properties of methylcholanthrene-induced tumors in mice at the strain of origin, Cancer Res. 13:835–837.PubMedGoogle Scholar
  2. 2.
    Old, L. J., Boyse, E. A., Clarke, D. A., and Carswell, E. A., 1962, Antigenic properties of chemicallyinduced tumors, Ann. N.Y. Acad. Sci. 101:80–106.CrossRefGoogle Scholar
  3. 3.
    Sjogren, H. O., 1965, Transplantation methods as a tool for detection of tumor-specific antigens, Prog. Exp. Tumor Res. 6:289–322.PubMedGoogle Scholar
  4. 4.
    Klein, G., 1966, Tumor antigens, Annu Rev. Microbiol. 20:223–252.PubMedCrossRefGoogle Scholar
  5. 5.
    Hellstrom, K. E., and Hellstrom, I., 1969, Cellular immunity against tumor antigens, Adv. Cancer Res. 12:167–223.PubMedCrossRefGoogle Scholar
  6. 6.
    Tuttle, R. L., and North, R. J., 1976, Mechanisms of antitumor action of Corynebacterium parvum: Replicating short-lived T cells as the mediators of potentiated tumor-specific immunity, J. Reticuloendothel. Soc. 20:209–216.PubMedGoogle Scholar
  7. 7.
    Burton, R. C., Chism, S. E., and Warner, N. L., 1978, In vitro induction and expression of T cell immunity to tumor-associated antigens, Contemp. Top. Immunobiol. 8:69–106.PubMedGoogle Scholar
  8. 8.
    Greenberg, P. D., Kern, D. E., and Cheever, M. A., 1985, Therapy of disseminated murine leukemia with cyclophosphamide and immune Ly-l+,2- T cells: Tumor eradication does not require participation of cytotoxic T cells, J. Exp. Med. 161:1122–1134.PubMedCrossRefGoogle Scholar
  9. 9.
    Bhan, A. K., Perry, L. L., Cantor, H., McCluskey, R. T., Benacerraf, B., and Greene, M. I., 1981, The role of T cell sets in rejection of a methylcholanthrene-induced sarcoma (S1509a) in syngeneic mice, Am. J. Pathol. 102:20–27.PubMedGoogle Scholar
  10. 10.
    Loveland, B. E., Hogarth, P. M., Ceredig, R., and McKenzie, I. F. C., 1981, Cells mediating skin graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection, J. Exp. Med. 153:1044–1057.PubMedCrossRefGoogle Scholar
  11. 11.
    Lukacher, A. E., Morrison, L. A., Braciale, V. L., Malissen, B., and Braciale, T. J., 1985, Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones, J. Exp. Med. 162:172–187.CrossRefGoogle Scholar
  12. 12.
    Golding, H., Munitz, T. I., and Singer, A., 1985, Characterization of antigen-specific, la-restricted, L3T4+ cytolytic T lymphocytes and assessment of thymic influence on their self specificity, J. Exp. Med. 162:943–961.PubMedCrossRefGoogle Scholar
  13. 13.
    Gorelik, E., 1983, Concomitant tumor immunity, Adv. Cancer Res. 39:71–120.PubMedCrossRefGoogle Scholar
  14. 14.
    North, R. J., and Kirstein, D. P., 1977, T cell-mediated concomitant immunity to syngeneic tumors: Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites, J. Exp. Med. 145:275–292.PubMedCrossRefGoogle Scholar
  15. 15.
    Bast, R. C., Bast, B. S., and Rapp, H. J., Critical review of previously reported animal studies of tumor immunotherapy with non-specific immunostimulants, 1976, Ann. N.Y. Acad. Sci. 277:60–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Vaage, J., 1971, Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue, Cancer Res. 31:1655–1662.PubMedGoogle Scholar
  17. 17.
    Takai, F., Levy, J. G., and Kilburn, D. G., 1976, In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor bearing mice, J. Immunol. 116:288–293.Google Scholar
  18. 18.
    Tuttle, R. L., Knick, V. C., Stopford, C. R., and Wolberg, G., 1983, In vivo and in vitro antitumor activity expressed by cells of concomitant immune mice, Cancer Res. 43:2600–2605.PubMedGoogle Scholar
  19. 19.
    North, R. J., and Dye, E. S., 1985, Ly-1+2- suppressor T cells down-regulate the generation of Ly 1+2- effector T cells, Immunology 53:47–56.Google Scholar
  20. 20.
    North, R. J., and Bursuker, I., 1984, The generation and decay of the immune response to a progressive fibrosarcoma: Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells, J. Exp. Med. 159:1295–1311.PubMedCrossRefGoogle Scholar
  21. 21.
    North, R. J., 1984, The therapeutic significance of concomitant antitumor immunity: Ly-1-2+ T cells from mice with a progressive tumor cause regression of an established tumor in 7-irradiated recipients, Cancer Immunol. Immunother. 18:69–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Dye, E. S., 1986, The antimetastatic function of concomitant immunity. II. Evidence that the genration of Ly-1+2+ effector T cells temporarily causes destruction of already disseminated tumor cells, J. Immunol. 136:1510–1515.PubMedGoogle Scholar
  23. 23.
    Greene, M. I., 1980, The genetic and cellular basis of regulation of the immune response to tumor antigens, Contemp. Top. Immunobiol. 11:81–116.Google Scholar
  24. 24.
    Hawrylko, E., 1982, Tumor bearer T cells suppress BCG-potentiated antitumor responses. 1. Requirements for their effectors, Cell. Immunol. 66:121–138.PubMedCrossRefGoogle Scholar
  25. 25.
    Hawrylko, E., Mele, C. A., and Stutman, O., 1982, Tumor bearer T cells suppress BCG-potentiated antitumor responses. II. Characteristics of the efferent phase suppressor, Cell. Immunol. 66:139–151.PubMedCrossRefGoogle Scholar
  26. 26.
    Berendt, M. J., and North, R. J., 1980, T cell-mediated immunosuppression of antitumor immunity: An explanation for progressive growth of an immunogenic tumor, J. Exp. Med. 151:69–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Dye, E. S., and North, R. J., 1981, T cell mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases, J. Exp. Med. 154:1033–1042.PubMedCrossRefGoogle Scholar
  28. 28.
    Bonventre, P. F., Nockol, A. D., Ball, E. J., Michael, J. G., and Bubel, H. C., 1982, Development of protective immunity against bacterial and viral infections in tumor-bearing mice is coincident with suppression, J. Reticuloendothel. Soc. 32:25–34.PubMedGoogle Scholar
  29. 29.
    North, R. J., 1982, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on the elimination of tumor-induced suppressor T cells, J. Exp. Med. 55:1063–1074.CrossRefGoogle Scholar
  30. 30.
    North, R. J., 1984, γ-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells, Cancer Immunol. Immunother. 16:175–181.PubMedCrossRefGoogle Scholar
  31. 31.
    Dye, E. S., and North, R. J., 1984, Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors, J. Leukocyte Biol. 36:27–38.PubMedGoogle Scholar
  32. 32.
    Bursuker, I., and North, R. J., 1985, Suppression of generation of concomitant immunity by passively transferred suppressor T cells from tumor-bearing donors, Cancer Immunol. Immunother. 19:215–218.PubMedCrossRefGoogle Scholar
  33. 33.
    Hellstrom, K. E., Hellstrom, I., Kant, J. A., and Temerius, J. D., 1978, Regression and inhibition of sarcoma growth by interference with a radiosensitive T cell population, J. Exp. Med. 148:799–804.PubMedCrossRefGoogle Scholar
  34. 34.
    Frost, P., Prete, P., and Kerbel, R., 1982, Abrogation of the in vitro generation of the cytotoxic T cell response to a murine tumor: The role of suppressor cells, Int. J. Cancer 30:211–217.PubMedCrossRefGoogle Scholar
  35. 35.
    Mills, C. D., and North, R. J., 1983, Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient: Inhibition by suppressor T cells, J. Exp. Med. 157:1448–1460.PubMedCrossRefGoogle Scholar
  36. 36.
    Dye, E. S., and North, R. J., 1984, Adoptive immunization against an established tumor with cytolytic versus memory T cells: Immediative versus delayed onset of regression, Transplantation 37:600–605.PubMedCrossRefGoogle Scholar
  37. 37.
    Hall, B. M., Jelbart, M. E., Gurley, K. E., and Dorsch, S. E., 1985, Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine: Mediation of suppression by T helper/inducer cells, J. Exp. Med. 162:1683–1694.PubMedCrossRefGoogle Scholar
  38. 38.
    Mullen, C. A., Urban, J. L, VanWaes, C., Rowley, D. A., and Schreiber, H., 1985, Multiple cancers: Tumor burden permits the outgrowth of other cancers, J. Exp. Med. 162:1665–1682.PubMedCrossRefGoogle Scholar
  39. 39.
    DiGiacomo, A., and North, R. J., 1986, T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity, J. Exp. Med. 164:1179–1192.Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Robert J. North
    • 1
  • Antonio DiGiacomo
    • 1
  • Earl S. Dye
    • 1
  1. 1.Trudeau Institute, Inc.Saranac LakeUSA

Personalised recommendations